6-(Aminomethyl)-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one | 943894-85-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 6-(Aminomethyl)-3-methyl-2,3-dihydro-1,3-benzoxazol-2-one
• 英文别名: 6-(aminomethyl)-3-methyl-1,3-benzoxazol-2-one
• CAS: 943894-85-7
• 化学式: C₉H₁₀N₂O₂
• 分子量: 178.19
• InChiKey: XNYQTDQCTDELDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13
  申请人：Shionogi&Co., Ltd.

  公开号：EP2128134A1

  公开（公告）日：2009-12-02

  A compound represented by the general formula (I): wherein R1 is wherein R26 and R28 are each independently lower alkyloxy and the like; n1 is an integer of 0 to 3; Z is a optionally substituted C1-C5 alkynylene which may be interrupted with a substituent selected from Substituent group a and the like; A is a group represented by the formula: wherein R6 and R7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R2 is a hydrogen atom and the like; R3 is optionally substituted lower alkyl and the like; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxyl and the like, or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof.

  通式 (I) 所代表的化合物： 其中 R1 是 其中 R26 和 R28 各自独立地为低级烷氧基等；n1 为 0 至 3 的整数；Z 为任选取代的 C1-C5 烯烃，可被选自取代基 a 等的取代基打断；A 为由式（I）表示的基团： 其中 R6 和 R7 各自独立地为低级烷基等；m 和 n 各自独立地为 0、1 或 2；R2 为氢原子等；R3 为任选取代的低级烷基等；R4 为氢原子；或 R3 和 R4 可与相邻碳原子一起构成环；R5 为羟基等，或其光学活性异构体、药学上可接受的盐或溶液。
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterotricyclic metalloprotease inhibitors
  申请人：Gege Christian

  公开号：US20080207607A1

  公开（公告）日：2008-08-28

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterotricyclic Metalloprotease Inhibitors
  申请人：Gege Christian

  公开号：US20100087420A1

  公开（公告）日：2010-04-08

  The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.